Liu H X, Wei D L, Shao S, Jiang Y, Li S, Zhu J, Wang C, Zhao C X
Department of Hematology, Shanghai Zhaxin Traditional Chinese& Western Medicine Hospital, Shanghai 200435, China.
Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):654-659. doi: 10.3760/cma.j.issn.0253-2727.2023.08.007.
To explore the efficacy of immunosuppression intensified conditioning regimen in patients who have strongly positive donor-specific Anti-HLA antibodies (DSAs) and received a haploidentical hematopoietic stem cell transplantation (haplo-HSCT) . Clinical data of 10 patients with strongly positive pretransplant DSAs (defined as MFI ≥10000) were retrospectively analyzed in this study. All of them received a haplo-HSCT in the Hematology Department of Shanghai Zhaxin Traditional Chinese & Western Medicine Hospital. ① Of all ten patients, three were males, and seven were females, with a median age of 53.5 (36-64) years. Of the 10 patients, three were diagnosed with acute myeloid leukemia, two were myelodysplastic syndromes (MDS), two were chronic myelomonocytic leukemia (CMML), two were in an accelerated phase of chronic myeloid leukemia (CML-AP), and one was primary myelofibrosis (PMF). ② Conditioning regimen consisted of fludarabine (Flu) /busulfan (Bu) combined with whole-body irradiation (TBI) /cyclophosphamide (Cy). ③ On the seventh day after transplantation, the median pretransplant DSA level was MFI 15 999 (10 210-23 417) and 10 787 (0-22 720). ④ Eight patients acquired hematopoietic reconstitution; the median time of neutrophil engraftment was 14 (10-16) days; and 18 (14-20) days for platelet engraftment. After a median follow-up of 12.5 (1.5-27) months, primary graft failure was found in one patient and another with poor graft function. Seven patients remained in a disease remission state, and all were DSA-negative. An intensified immunosuppression conditioning regimen can efficiently decrease the level of donor-specific anti-HLA antibodies (DSAs), leading to good short-term efficacy.
探讨强化免疫抑制预处理方案在供者特异性抗人白细胞抗原抗体(DSA)强阳性且接受单倍型造血干细胞移植(haplo-HSCT)患者中的疗效。本研究回顾性分析了10例移植前DSA强阳性(定义为平均荧光强度≥10000)患者的临床资料。所有患者均在上海闸新中西医结合医院血液科接受单倍型造血干细胞移植。①10例患者中,男性3例,女性7例,中位年龄53.5(36 - 64)岁。10例患者中,3例诊断为急性髓系白血病,2例为骨髓增生异常综合征(MDS),2例为慢性粒单核细胞白血病(CMML),2例为慢性髓系白血病加速期(CML-AP),1例为原发性骨髓纤维化(PMF)。②预处理方案包括氟达拉滨(Flu)/白消安(Bu)联合全身照射(TBI)/环磷酰胺(Cy)。③移植后第7天,移植前DSA水平中位数分别为平均荧光强度15999(10210 - 23417)和10787(0 - 22720)。④8例患者获得造血重建;中性粒细胞植入中位时间为14(10 - 16)天;血小板植入时间为18(14 - 20)天。中位随访12.5(1.5 - 27)个月后,1例患者发生原发性移植物失败,另1例移植物功能不良。7例患者处于疾病缓解状态,且均为DSA阴性。强化免疫抑制预处理方案可有效降低供者特异性抗HLA抗体(DSA)水平,带来良好的短期疗效。